A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009000/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
- To compare the 3-year progression free survival (PFS) in the two treatment arms.
Secondary Objectives:
- Overall survival (OS).
- Postoperative pathological stage and R0 (complete) resection rate.
- Safety: Toxicities associated with neoadjuvant chemotherapy, surgery,
morbidity/mortality, toxicity of adjuvant chemotherapy.
提供机构：
Vivli
创建时间：
2023-06-06
